Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center

Articles

Rapid Readouts: Phase 3 ASCENT Study for Metastatic Triple-Negative Breast Cancer

August 11th 2021

Hope S. Rugo, MD, FASCO, discusses data presented at the 2021 American Society of Clinical Oncology annual meeting from the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

Future Directions for the Management of HR+ Breast Cancer

August 11th 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical Practice

August 11th 2021

A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.

Using CDK4/6 Inhibitors in Early Stage HR+ Breast Cancer

August 4th 2021

Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.

Early Stage HR+ Breast Cancer: Optimizing Multigene Assays

August 4th 2021

Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.

Using Genomic Assays for Early Stage HR+ Breast Cancer

July 28th 2021

The role of genomic assays, including Oncotype DX as reported on in the RxPONDER trial, for the optimal management of early stage HR+ breast cancer is discussed.

Emerging Agents for the Management of HR+ mBC

July 28th 2021

Aditya Bardia, MD, MPH, leads the discussion on the use of novel CDK4/6 inhibitors, BCL2 inhibitors, and oral SERDS for the treatment of HR+ metastatic breast cancer.

PI3KCA Inhibition: Managing AEs in HR+ mBC

July 21st 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, review the optimal management of adverse events associated with alpelisib in HR+ metastatic breast cancer.

Using CDK4/6 Inhibitors After HR+ mBC Disease Progression

July 21st 2021

Breast cancer experts comment on whether there is a benefit to switching to or continuing on CDK4/6 inhibitors with disease progression for HR+ metastatic breast cancer and discuss the use of tamoxifen for third-line endocrine therapy.

Case Discussion: Resistance to CDK4/6 Inhibitors in HR+ mBC

July 14th 2021

Andrew D. Seidman, MD, presents a case study of a 56-year-old postmenopausal woman diagnosed with stage IIB HR+ breast cancer and leads the discussion on approaching treatment for the given patient.

Implications of PIK3CA Mutations in HR+ mBC

July 14th 2021

Dejan Juric, MD, leads the discussion on the role of PIK3CA mutations in HR+ metastatic breast cancer.

Selecting a CDK4/6 Inhibitor for HR+ mBC

July 7th 2021

Experts in breast cancer comment on the appropriate patient selection of CDK4/6 inhibitors for the management of HR-positive metastatic breast cancer.

Using CDK4/6 Inhibitors in First-Line Treatment of HR+ mBC

July 7th 2021

A review of data from key phase 3 clinical trials, including ASCO 2021 updates, assessing the use of CDK4/6 inhibitors with endocrine therapy for the frontline treatment of HR-positive metastatic breast cancer.

Updated Data for Metastatic HER2+ Breast Cancer

January 25th 2021

Prognostic Tools for Early-Stage HER2+ Breast Cancer

January 25th 2021

Current Treatment Landscape for HER2+ Breast Cancer

January 25th 2021

Notable ASCO Trial Updates

July 14th 2020

HER2+ MBC Adverse-Event Management

July 14th 2020

After Progression on PIK3CAi Therapy: MTOR Inhibition

July 14th 2020

Significance of PIK3CA Mutation in HR+ Breast Cancer

July 14th 2020